Page last updated: 2024-09-05

l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 1 studies

*1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease. [MeSH]

*1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease. [MeSH]

Compound Research Comparison

Studies
(l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine)
Trials
(l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine)
Recent Studies (post-2010)
(l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine)
Studies
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
Trials
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
Recent Studies (post-2010) (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
6003,85981,052

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Iversen, SD; Miyaji, M; Naruse, T; Rupniak, NM; Tye, SJ1

Other Studies

1 other study(ies) available for l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

ArticleYear
NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.
    Clinical neuropharmacology, 1989, Volume: 12, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinson Disease, Secondary; Prodrugs; Saimiri; Time Factors

1989